Herantis Awaits CDNF Results This Year In Parkinson's Disease
Hopes To Improve Investor Profile With Dual Stock Market Listing
Executive Interview: Reducing “ER stress” is one of the potential mechanisms of action of a novel candidate Parkinson’s agent being evaluated by Finland’s Herantis, which completed an additional stock market listing, in Sweden, last month.
You may also be interested in...
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
Pekka Simula, CEO of Herantis, a company born from the merger of Hermo Pharma and Laurantis Pharma, talks to Scrip about the group's lead asset in Parkinson's disease.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.